Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center-Reference-Cited by-同舟云学术

Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center

Published:2015-12-09 Issue:1 Volume:172 Page:80-88
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Chihara Dai¹,Cheah Chan Y.¹^ORCID,Westin Jason R.¹^ORCID,Fayad Luis E.¹,Rodriguez Maria A.¹,Hagemeister Fredrick B.¹,Pro Barbara²,McLaughlin Peter¹,Younes Anas³,Samaniego Felipe¹,Goy Andre⁴,Cabanillas Fernando⁵,Kantarjian Hagop⁶,Kwak Larry W.¹,Wang Michael L.¹,Romaguera Jorge E.¹

Affiliation:

1. Department of Lymphoma and Myeloma; The University of Texas MD Anderson Cancer Center; Houston TX USA

2. Division of Hematology; Thomas Jefferson University; Philadelphia PA USA

3. Lymphoma Service; Memorial Sloan Kettering Cancer Center; New York NY USA

4. John Theurer Cancer Center; Hackensack University Medical Center; Hackensack NJ USA

5. Haematology; Auxilio Mutuo Cancer Centre; San Juan Puerto Rico

6. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston TX USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13796/fullpdf

Reference30 articles.

1. Real world data on primary treatment for mantle cell lymphoma: a nordic lymphoma group observational study;Abrahamsson;Blood,2014

2. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype;Bernard;Leukemia,2001

3. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213;Bernstein;Annals of Oncology,2013

4. Clinicopathologic features, management and outcomes of blastoid variant (BV) of mantle cell lymphoma (MCL): a nebraska lymphoma study group (NLSG) experience;Bhatt;Blood (ASH Annual Meeting Abstracts),2014

5. Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007;Chandran;Leukaemia & Lymphoma,2012

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Up-Front ASCT Overcomes the Survival Benefit Provided by HDAC-Based Induction Regimens in Mantle Cell Lymphoma: Data from a Real-Life and Long-Term Cohort;Cancers;2023-09-28

2. Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria;HemaSphere;2023-09-07

3. SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2023-09

4. Treatment of older patients with mantle cell lymphoma in the era of novel agents;Leukemia & Lymphoma;2023-06-26

5. Real‐world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis;Cancer Medicine;2023-05-06